Free Beauty Samples In Australia

FDA Sends CSL Biotherapies Warning Letter Over Plant Conditions.

The Food and Drug Administration (FDA) conducted an inspection of CSL Biotherapies, located at 45 Poplar Road, Parkville, Victoria 3052, Australia, between March 21 and March 31, 2011. During the inspection, FDA investigators documented deviations from current good manufacturing practice (CGMP) requirements in the manufacture of licensed biological vaccine Afluria and monovalent influenza bulks. Deviations from CGMP include the applicable requirements of Section 501(a)(2)(B) of the Federal Food, Drug and Cosmetic Act (FD&C Act), Section 351(a) of the Public Health Service Act (PHS Act), and Title 21, Code of Federal Regulations (21 CFR) Parts 210, 211, and 600-680. 1) You failed to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, and failed to extend the investigation to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy [21 CFR 211.192]. For example: i. There is no documentation of the Adverse Event investigation. SOP # (b)(4) 11209 titled “Corrective and Preventive Action,” requires documentation of actual or potential problems which may affect the quality and reliability of products, processes or quality systems. The procedure requires that activities and decisions are to be documented such that there is traceability of Corrective and Preventive Actions (CAPA) from the initial identification of problems to the implementation of solutions and the follow up to evaluate effectiveness. ii. There was a limited analysis of the manufacturing process to determine why there was a substantial increase in Adverse Event reports of fever and convulsions in the 2010 Southern Hemisphere influenza season in comparison to previous seasons. There was no analysis of all critical parameters and critical processing steps to try to determine differences in the 2010 lots associated with Adverse Event reports compared to lots from previous seasons. For example: iii. The Quality Review Report indicates that the A/California/7/2009 (H1N1) strain appears to have a (b)(4) content, which could have contributed to the Adverse Events. The information was received in July 2010. You confirmed that A/California/7/2009 (H1N1) had a (b)(4) level of (b)(4), but have not initiated testing of the 2010 influenza vaccine lots to determine differences in (b)(4) content compared to 2009 strains. iv. There was no evaluation of the testing of raw material, and potential impact on manufacturing, of (b)(4) lots of Sodium Taurodeoxycholate (TDOC), which failed ID tests performed via (b)(4) but were accepted for use. An investigation was not initiated to determine the reason for identification failures and the vendor was never contacted to inquire about the possible changes to TDOC lots. Without further investigation into possible changes to TDOC, the (b)(4) of the lots failing identification were included into the (b)(4) of acceptable (b)(4) ii. A leachable study on product at the end of shelf life was initiated to determine if the container closure system contributed to dark particles found in influenza virus vaccine in multi-dose vials. Only one multi-dose vial lot and one syringe lot representing product distributed to the U.S. were included in this study. There is no statistical rationale for use of this sample size. iii. The direct analysis of the particles indicates that they are discolored influenza split virus with the possible presence of (b)(4) mercury compounds that may contain (b)(4) and other inorganic compounds. You concluded that the dark particles are not foreign to the product. However, dark particles have not been linked to bulk lots and product in syringes (using different stoppers) and no rationale is provided for your conclusion. A) You failed to determine optimal splitting conditions for new virus strains before the strains are used in production. For the change to influenza virus strain A/Victoria/210/2009 for the 2010/2011 Northern Hemisphere, a concentration of (b)(4) TDOC was assigned to A/Victoria/210/2009. However, upon manufacture of the first two monovalent lots ((b)(4)), the (b)(4). A small scale study was then performed to determine the TDOC concentration required for optimal disruption of virus. The study determined that a concentration of (b)(4) TDOC, not (b)(4) should be used for manufacture of A/Victoria/210/2009. Nevertheless, the lots manufactured at (b)(4) TDOC concentration were released for further processing. A) Deviation # PRD-3470 was initiated in June 2010 due to the atypical appearance of Monovalent Pooled Harvest (MPH) lot # (b)(4) during the (b)(4). Suspended white agglomerate material was present in Quality Control samples. The associated sister lot did not have the same problem. Investigation found that a (b)(4) was (b)(4) for lot # (b)(4). There was no investigation into the possible failure of (b)(4). The vendor was not notified and the (b)(4) were not further analyzed. B) A series of (b)(4) lots exceeded bioburden alert/action limit at the (b)(4) between October 16, 2010, and December 4, 2010. There has been no effort to determine if the contamination could be isolated to specific (b)(4) or if all (b)(4) were implicated. The failure investigation did not evaluate the effectiveness of cleaning of the (b)(4). The (b)(4) cleaning re-validation failed in July 2010. 4) You failed to reject a lot of components which failed to meet appropriate written specifications. (b)(4) lots of Sodium Taurodeoxycholate (TDOC), used to disrupt influenza virus to make a split virion vaccine, were delivered in 2010. (b)(4) fifteen lots failed the ID test performed (b)(4) but the lots were accepted for use. An investigation was not initiated to determine the reason for identification failures and the vendor was never contacted to inquire about the possible changes to TDOC lots. Without further investigation into possible changes to TDOC, the –b(4)-- of the lots failing identification were included into the (b)(4) of acceptable (b)(4) The deficiencies described in the Form FDA 483 and this letter are an indication of your Quality Control Unit not fulfilling its responsibility to assure the identity, strength, quality, and purity of your monovalent influenza bulks and final drug products. Please describe in detail how CSL Biotherapies will attain CGMP compliance with regard to the above observations. Please include in that description how you will use all relevant information to conduct thorough investigations to ensure that adequate steps are taken to evaluate whether deviations impact product and to implement effective corrective and preventive actions. We acknowledge receipt of your written responses dated April 18, 2011, and May 13, 2011, which address the inspectional observations on the Form FDA 483 issued at the close of the inspection, and we have reviewed their contents. Corrective actions addressed in your letter may be referenced in your response; however, we believe that your response did not provide sufficient detail to fully assess the adequacy of your corrective actions. In addition, we have the following comments regarding the corrective actions detailed below. The items are numbered to correspond to the observations listed on the Form FDA 483. Observation 1 – General Comments –The deviations listed throughout 483 Observation #1, and in other 483 items, appear to suggest that a more global approach should be taken to evaluate your Quality System and how it interacts with all other parts of your manufacturing process. For example, your responses reference several new procedures and procedural changes which will enable you to perform more effective and complete investigations. It is of note, however, that the Untitled Letter (UL) issued to CSL on June 24, 2010 cited several inadequacies in your investigation into black particle formation in multi-dose vials of Influenza Virus Vaccine. These concerns have been reiterated in form FDA 483 observation #4. Your proposed corrective actions as a result of the 2010 UL should have included a comprehensive evaluation of your investigation process and should have driven corrective and preventive actions which could have prevented the deviations noted in this observation. Also, Observation #1E reads in part, “There was no evaluation of testing of raw material and potential impact on manufacturing.” Your response indicates that you intend to update SOP (b)(4)-9254, titled “5950 Identification and Qualification of Raw Materials Using the (b)(4),” to provide instruction on performing an investigation in the event of a raw material acceptance test failure. Observations 2B, 2C, 3A1, 3A2, & 3B – General Comments –Due to the complex technical nature and overlapping issues presented in these observations, we advise that you contact Maryna Eichelberger in CBER’s Office of Vaccines Research and Review at 301-402-3846 in order to obtain input on your proposed corrective and preventive actions. Neither this letter, nor the observations listed on the Form FDA 483 presented to your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deviations that may exist at your facility. It is your responsibility as management to ensure that your establishment is in compliance with the provisions of the Federal Food, Drug, and Cosmetic Act, The Public Health Service Act, all applicable federal laws and regulations, and the standards in your license. Federal agencies are advised of the issuance of all Warning Letters about biological products so that they may take this information into account when considering the award of contracts. Please notify this office in writing, within 15 working days of receipt of this letter, of any additional steps you have taken or will take to correct the noted violations and to prevent their recurrence. Include any documentation necessary to show that corrective action has been achieved. If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your reply should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, HFM-600, 1401 Rockville Pike, Suite 200N, Rockville, Maryland 20852-1448. To schedule a meeting at your earliest convenience, please contact Robert McElwain, Consumer Safety Officer, in the Division of Case Management at (301) 827-6196.

Join the Coles Baby & Toddler Club for free | Australia Free Samples

If you’re pregnant or you have a child under 3 years old, you should join the Coles Baby & Toddler Club.

Membership is free and you receive these great benefits:

A Coles Baby & Toddler magazine.

Ebony

We will rush you exciting information about Studio Girl and two new beauty samples, free. No obligation. 11461 Hart Street Dept.- BP435 No. ...

Making It Work, Inspirations for Christian Marriage and Life

TheFreeStie.com A popular free stuff site that lists all categories of free stuff. ... DVDs, fun freebies, health & beauty items, samples, student freebies, ...

Microbiology Australia

KYE-HO SHIN*, KYUNG-HEE SUH, HAK-HEE KANG, YOUNG-CHEOL SIM Cosmetic Research .... Probing of DNA extracted from rumen samples using competitive PCR probes ...

Microbiology Australia

KYUNG-HEE SUH, HAK-HEE KANG, YOUNG-CHEOL SIM Cosmetic Research Institute, .... Probing of DN A extracted from rumen samples using competitive PCR probes ...

Microbiology Australia

YOUNG-CHEOL SIM Cosmetic Research Institute, Pacific R & D Center, Yongin. .... Probing of DNA extracted from rumen samples using competitive PCR probes ...